Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support. - Brown R; Smith KE; Shanshal MM; Dimou A; Leventakos K; Parikh K; Mansfield AS; Molina JR; Goetz MP; Jatoi A; Cathcart-Rake E (Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025)